Explore Anti-CD319 Monoclonal Antibody for Enhanced Research Applications

Alpha Lifetech Incorporation presents its anti-CD319 monoclonal antibody, a powerful tool for researchers and clinicians focusing on hematological malignancies and immune system regulation. CD319, also known as SLAMF7, is a Protein expressed on the surface of various immune cells, playing a significant role in cell signaling and activation. By targeting CD319, this antibody facilitates the study of multiple myeloma and other lymphoproliferative disorders, providing critical insights into disease mechanisms and potential therapeutic strategies, Designed for high affinity and specificity, this monoclonal antibody is ideal for applications such as flow cytometry, immunohistochemistry, and Western blotting. Researchers can rely on validated performance to ensure reproducible results in their studies. With Alpha Lifetech’s commitment to quality and innovation, the anti-CD319 monoclonal antibody serves as a valuable asset in advancing cancer research and enhancing therapeutic development. Explore the potential of this robust antibody to deepen your understanding of immune responses and malignancies

Hot Selling Product

ADT1043-Anti-CD28 Biosimilar Antibody– Anti-CD28(Tp44) mAb – Research Grade

ADT1742-Human Anti-Her2xHer3 Bispecific Antibody

ADT1743-Human Anti-PD-1xCTLA-4 Bispecific Antibody

ADT1744-Human Anti-VEGFAxANGPT2 Bispecific Antibody

ADT1755-Human Anti-CTLA4xLAG3 Bispecific Antibody

ADT1756-Human Anti-CD3xCD20 Bispecific Antibody

China Top anti-CD319 monoclonal antibody Delivers Unmatched Quality Factory

Discover the exceptional quality of Alpha Lifetech Inc.'s China top anti-CD319 monoclonal antibody—a breakthrough in the field of biomedical research and therapeutic development. Founded by a dedicated team of scientists with extensive expertise in membrane protein production, Nanobody discovery, and monoclonal development, Alpha Lifetech Inc. stands at the forefront of innovative solutions for global researchers and practitioners. Our commitment to quality is unparalleled, and we have successfully launched nearly 10,000 high-quality spot membrane protein reagents, cytokines, and drug target antibodies, catering to a diverse range of applications. The anti-CD319 monoclonal antibody is a testament to our rigorous development processes and quality control measures. This highly specific antibody offers unmatched sensitivity and specificity, making it an invaluable tool for diagnostics and therapeutic applications. With a focus on providing the best reagents to support scientific advancement, Alpha Lifetech Inc. ensures that researchers around the world can rely on our products to drive their projects forward. As we continue to expand our portfolio, we invite global procurement professionals to explore the benefits of partnering with Alpha Lifetech Inc. and experience firsthand the difference that high-quality reagents can make in their research endeavors.

China Top anti-CD319 Monoclonal Antibody Delivers Unmatched Quality Factory

Product Name	Purity (%)	Concentration (mg/ml)	Lot Number	Expiration Date
Anti-CD319 Monoclonal Antibody A	95.0	1.0	LOT123456	2025-12-31
Anti-CD319 Monoclonal Antibody B	98.5	0.5	LOT789012	2026-06-30
Anti-CD319 Monoclonal Antibody C	97.0	2.0	LOT345678	2024-09-15

Monoclonal Antibody Production Trends in China (2020-2023)

The production trends of monoclonal antibodies in China from 2020 to 2023 have shown a significant increase, demonstrating the growing capabilities and advancements in the biotechnology sector. The data depicted in the bar graph illustrates that production volume has risen steadily over the years. In 2020, the production volume stood at 1.5 million units, which increased to 2.1 million units in 2021. This upward trajectory continued as production reached 2.9 million units in 2022 and an impressive forecast of 3.5 million units in 2023. This growth can be attributed to various factors, including increased investments in research and development, a larger focus on biotechnology innovations, and the expansion of manufacturing facilities across the nation. The raised output of monoclonal antibodies plays a critical role in the development of targeted therapies, particularly in treating diseases such as cancers and autoimmune disorders. As such, these trends underscore the strategic importance of monoclonal antibodies in modern medicine and highlight the commitment of the Chinese biotechnology industry to enhance both quality and quantity in antibody production.